BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

Rhea-AI Summary

BioCardia (NASDAQ:BCDA) will host a Q3 2025 corporate update and financial results conference call on Wednesday, November 12, 2025 at 4:30 PM EDT.

The event includes management remarks followed by a Q&A. Registered participants will receive dial-in details; U.S. callers can use 1-833-316-0559 and international callers 1-412-317-5730. A live webcast will be available and a webcast replay will be posted about one hour after the call and remain available through approximately November 26, 2025. Telephonic replay details and access codes were provided for domestic and international listeners.

SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10204565/1005a9b26d8.

Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=v3qWCosD.

A webcast replay of the call will be available approximately one hour after the end of the call through approximately November 26, 2025 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 4273038.

About BioCardia^®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP^® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.

MEDIA CONTACT:
Miranda Peto, Investor Relations 
mpeto@biocardia.com 
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com 
(650) 226-0120

FAQ

When is BioCardia's Q3 2025 earnings conference call for BCDA?

The call is scheduled for Wednesday, November 12, 2025 at 4:30 PM EDT.

How can investors listen to BioCardia (BCDA) conference call on November 12, 2025?

Register online to receive dial-in details or call 1-833-316-0559 (U.S.) or 1-412-317-5730 (international) and ask to join the BioCardia call.

Where is the BioCardia (BCDA) live webcast for the Q3 2025 update?

The live webcast can be accessed via the company's webcast link provided for the event.

When will the BioCardia (BCDA) webcast replay be available and how long will it remain online?

A webcast replay will be available about one hour after the call and remain accessible through approximately November 26, 2025.

Is there a telephonic replay for BioCardia's November 12, 2025 call and what is the access code?

Yes; a telephonic replay is available with access code 4273038 and domestic/international dial-in numbers provided.

Will BioCardia (BCDA) include a question-and-answer session on the November 12, 2025 call?

Yes; management will deliver remarks followed by a question-and-answer session for participants.